

Manhattan Scientifics Triples Revenue

Company's 10K Discloses Earnings Increase Over 90%

April 4, 2011

"We are sufficiently capitalized to manage and run our current business operations without the need for additional capital and we continue exploring with pharmaceutical companies and device manufacturers for potential industrial partners for our 'cancer project'"

NEW YORK--Manhattan Scientifics, Inc. (OTCBB: MHTX) today announced its results of operations for the year ended December 31, 2010. The company announced that it tripled its revenue in year 2010 and reduced its loss to \$43,000 from a loss of \$446,000 in year 2009.

"As a result of our increased revenues, our independent auditors have removed the "going concern" qualification from its previous audit opinion," said CEO Manny Tsoupanarias.

"We are sufficiently capitalized to manage and run our current business operations without the need for additional capital and we continue exploring with pharmaceutical companies and device manufacturers for potential industrial partners for our "cancer project". Our focus is to commercialize nanotechnologies for metals and medical treatment sourced from laboratories in New Mexico."

He continued with an update: "Our advanced metals business is running well and generating revenue as we commercialize this exciting breakthrough technology. Our metals business is a core component for Manhattan Scientifics and is expected to continue to help us expand our business."

About Manhattan Scientifics

Manhattan Scientifics, Inc., (OTCBB: MHTX), is a leading information age enterprise focused on the nanomedicine space. Located in New Mexico, New York and Montreal, Manhattan Scientifics' goal is to create profit for the company's shareholders through royalty-bearing licenses with Fortune 1000 companies by marketing products that rely on the company's patents, know-how and intellectual property. Manhattan Scientifics owns the exclusive, perpetual U.S. license to a family of patents which will enable the manufacture and marketing of super strong, ultra light-weight "nanostructured" metals that have been developed at the Los Alamos National Laboratory (LANL) and in the former Soviet Union. More information about Manhattan Scientifics can be found at www.mhtx.com and at www.seniorscientific.com

Forward-looking statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Contacts

Manhattan Scientifics, Inc.

Marvin Maslow, Director of PR & IR, 917-923-3300



Email: marvin@mhtx.com

U.S. & Canadian Investor Relations

Hawk Associates: Frank Hawkins, 305-451-1888

Email: f.hawkins@hawkassociates.com